Biogen Idec Ma Inc.

Biogen Ma Inc.

Q32 Bio Inc.

Genentech, Inc.

Susan L Kalled

Yen-Ming Hsu

Sambasiva Rao

Justin Andrew Caravella

Frederick Robbins Taylor

Shelia Marie Violette

Vernon Michael Holers

Michael Storek

Michael Steven Curtis

Ellen Garber Stark

Kelly C Fahnoe

Cheng Ran Huang

Tatiana Novobrantseva

Leonid Gorelik

Fabienne MacKay

Flavius Martin

Joanne Quan

Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.

Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator

This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind na&#xef;ve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting na&#xef;ve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.

Anti-BCMA antibodies

Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide

Fusion protein constructs comprising anti-C3d antibody and factor H

The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.

BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders

Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administration.

Methods of treating a patient having an autoimmune disorder by administering a soluble BCMA

The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.

Methods of evaluating BAFF

Method of treating a patient having an autoimmune disorder by administering BAFFR polypeptide

BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-&#x3ba;B2, CD23, H2-M&#x3b2; (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M&#x3b2; molecule in a biological sample of the mammal, and optionally further detecting NF-&#x3ba;B2 molecule and/or CD23 molecule in the biological sample.

Methods for use with BAFF antagonists

Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BCMA

Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BAFFR

Growing community of inventors

Concord, MA, United States of America

Susan L Kalled